Pediatrix Medical Group (NYSE: MD) shares surged 11.59% in pre-market trading on Monday following the release of its better-than-expected third-quarter results and an improved full-year outlook. The healthcare services provider reported strong financial performance, surpassing analyst estimates and demonstrating resilience in a challenging healthcare environment.

The company reported adjusted earnings of $0.67 per share for the third quarter, significantly beating the analyst consensus estimate of $0.47. This represents a 52.27% increase from $0.44 per share in the same period last year. Pediatrix's quarterly revenue came in at $492.875 million, exceeding the analyst consensus estimate of $476.493 million by 3.44%. Despite a slight year-over-year decrease in revenue, the company's focus on operational efficiency and favorable reimbursement factors drove profitability.

Investors were particularly encouraged by Pediatrix's raised full-year 2025 outlook. The company now expects adjusted EBITDA to range between $270 million and $290 million, a significant increase from its previous estimate of $245 million to $255 million. CEO Mark S. Ordan attributed the strong results to improved collection activity, higher patient acuity, and a favorable payor mix. The company's same-unit net revenue growth of 7.6% further underscores its operational strength. With these positive developments, Pediatrix Medical Group appears well-positioned for continued growth, driving investor optimism and the pre-market stock surge.